Trials / Unknown
UnknownNCT05415345
Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin
Study on the Immunogenicity and Safety of Co-immunization With Recombinant Human Papillomavirus 16/18 Bivalent Vaccine and Hepatitis E Vaccine
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 480 (estimated)
- Sponsor
- Xiamen Innovax Biotech Co., Ltd · Industry
- Sex
- Female
- Age
- 18 Years – 25 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the immunogenicity and safety of co-immunization with recombinant human papillomavirus bivalent (Types 16,18) vaccine (Escherichia coli) and Hepatitis E vaccine (Escherichia coli)
Detailed description
Cecolin is the first Chinese domestic human papillomavirus (HPV) vaccine. Cecolin is designed to protect against HPV types 16 and 18, the most common virus types that lead to cervical cancer. Hecolin is the first prophylactic vaccine against hepatitis E virus (HEV). The purpose of this study is to evaluate the immunogenicity and safety of co-immunization with Cecolin and Hecolin.
Conditions
- Human Papilloma Virus Infection Type 16
- Human Papilloma Virus Infection Type 18
- Hepatitis E Virus Infection
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Cecolin | Bivalent HPV Vaccine |
| BIOLOGICAL | Hecolin | Hepatitis E vaccine |
Timeline
- Start date
- 2021-10-25
- Primary completion
- 2022-11-30
- Completion
- 2023-06-10
- First posted
- 2022-06-13
- Last updated
- 2022-06-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05415345. Inclusion in this directory is not an endorsement.